Statistical Validation of Surrogate Markers in Clinical Trials

A. Alonso; G. Molenberghs; G.J.P. van Breukelen

doi:10.1007/978-3-642-55345-5_13

Statistical Validation of Surrogate Markers in Clinical Trials

A. Alonso, G. Molenberghs, G.J.P. van Breukelen

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic

Abstract

The increasing cost of drug development has raised the demand on the use of biomarkers as surrogate endpoints for the evaluation of new drugs in clinical trials. However, failed past attempts to use surrogate endpoints made it clear that, before deciding on the use of a candidate surrogate endpoint, it is of the utmost importance to investigate its validity. Such validation process has proven challenging for conceptual and practical reasons. In the present chapter, some of the statistical methods introduced for the evaluation of surrogate markers will be discussed. Emphasis will be made on the so-called meta-analytic approach and its information-theoretic version, where information from several units is combined to carry out the validation exercise. The methods will be illustrated using a case study in ophthalmology.

Original language	English
Title of host publication	Developments in Statistical Evaluation of Clinical Trials
Editors	K. van Montfort, J. Oud, G. Wendimagegn
Publisher	Springer
Pages	227-246
Number of pages	20
ISBN (Print)	978-3-642-55345-5
DOIs	https://doi.org/10.1007/978-3-642-55345-5_13
Publication status	Published - 1 Jan 2014

Access to Document

10.1007/978-3-642-55345-5_13

Cite this

@inbook{86b3d2074d0c410e9ba14cde75a7fe89,

title = "Statistical Validation of Surrogate Markers in Clinical Trials",

abstract = "The increasing cost of drug development has raised the demand on the use of biomarkers as surrogate endpoints for the evaluation of new drugs in clinical trials. However, failed past attempts to use surrogate endpoints made it clear that, before deciding on the use of a candidate surrogate endpoint, it is of the utmost importance to investigate its validity. Such validation process has proven challenging for conceptual and practical reasons. In the present chapter, some of the statistical methods introduced for the evaluation of surrogate markers will be discussed. Emphasis will be made on the so-called meta-analytic approach and its information-theoretic version, where information from several units is combined to carry out the validation exercise. The methods will be illustrated using a case study in ophthalmology.",

author = "A. Alonso and G. Molenberghs and {van Breukelen}, G.J.P.",

year = "2014",

month = jan,

day = "1",

doi = "10.1007/978-3-642-55345-5_13",

language = "English",

isbn = "978-3-642-55345-5",

pages = "227--246",

editor = "Montfort, {K. van} and J. Oud and G. Wendimagegn",

booktitle = "Developments in Statistical Evaluation of Clinical Trials",

publisher = "Springer",

address = "United States",

}

TY - CHAP

T1 - Statistical Validation of Surrogate Markers in Clinical Trials

AU - Alonso, A.

AU - Molenberghs, G.

AU - van Breukelen, G.J.P.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The increasing cost of drug development has raised the demand on the use of biomarkers as surrogate endpoints for the evaluation of new drugs in clinical trials. However, failed past attempts to use surrogate endpoints made it clear that, before deciding on the use of a candidate surrogate endpoint, it is of the utmost importance to investigate its validity. Such validation process has proven challenging for conceptual and practical reasons. In the present chapter, some of the statistical methods introduced for the evaluation of surrogate markers will be discussed. Emphasis will be made on the so-called meta-analytic approach and its information-theoretic version, where information from several units is combined to carry out the validation exercise. The methods will be illustrated using a case study in ophthalmology.

AB - The increasing cost of drug development has raised the demand on the use of biomarkers as surrogate endpoints for the evaluation of new drugs in clinical trials. However, failed past attempts to use surrogate endpoints made it clear that, before deciding on the use of a candidate surrogate endpoint, it is of the utmost importance to investigate its validity. Such validation process has proven challenging for conceptual and practical reasons. In the present chapter, some of the statistical methods introduced for the evaluation of surrogate markers will be discussed. Emphasis will be made on the so-called meta-analytic approach and its information-theoretic version, where information from several units is combined to carry out the validation exercise. The methods will be illustrated using a case study in ophthalmology.

U2 - 10.1007/978-3-642-55345-5_13

DO - 10.1007/978-3-642-55345-5_13

M3 - Chapter

SN - 978-3-642-55345-5

SP - 227

EP - 246

BT - Developments in Statistical Evaluation of Clinical Trials

A2 - Montfort, K. van

A2 - Oud, J.

A2 - Wendimagegn, G.

PB - Springer

ER -